Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jeffrey Weber

Showing results (51-60 of 104) with videos related to

Pageof 11
Sort By:
Cancer Immunology Research|January 13, 2019
Association of Tumor Microenvironment T-cell Repertoire and Mutational Load with Clinical Outcome after Sequential Checkpoint Blockade in MelanomaErik Yusko, Marissa Vignali, Richard K Wilson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 13, 2009
A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanomaJeffrey Weber, John A Thompson, Omid Hamid, et al.
Cancer Immunity|July 9, 2013
Randomized phase I pharmacokinetic study of ipilimumab with or without one of two different chemotherapy regimens in patients with untreated advanced melanomaJeffrey Weber, Omid Hamid, Asim Amin, et al.
The Journal of Rheumatology|December 3, 2010
Botulinum toxin intramuscular injections for neck pain: a systematic review and metaanalysisPierre Langevin, Janet Lowcock, Jeffrey Weber, et al.
Cancer Imaging : the Official Publication of the International Cancer Imaging Society|January 23, 2015
Metabolic response by FDG-PET to imatinib correlates with exon 11 KIT mutation and predicts outcome in patients with mucosal melanomaKatherine Zukotynski, Jeffrey T Yap, Anita Giobbie-Hurder, et al.
Melanoma Research|August 18, 2020
Preliminary analysis of distinct clinical and biologic features of bone metastases in melanomaMelissa A Wilson, Judy Zhong, Paul Johannet, et al.
Melanoma Research|August 22, 2013
The antimelanoma activity of the histone deacetylase inhibitor panobinostat (LBH589) is mediated by direct tumor cytotoxicity and increased tumor immunogenicityDavid M Woods, Karrune Woan, Fengdong Cheng, et al.
The Oncologist|May 13, 2017
Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of EncephalitisJames Larkin, Bartosz Chmielowski, Christopher D Lao, et al.
The Journal of Dermatology|October 23, 2019
Adjuvant therapy with nivolumab versus ipilimumab after complete resection of stage III/IV melanoma: Japanese subgroup analysis from the phase 3 CheckMate 238 studyKenji Yokota, Hiroshi Uchi, Hisashi Uhara, et al.
Cancer|December 20, 2002
Granulocyte-macrophage-colony-stimulating factor added to a multipeptide vaccine for resected Stage II melanomaJeffrey Weber, Vernon K Sondak, Ronaldo Scotland, et al.
Pageof 11

Showing results (51-60 of 104) with videos related to

Sort By:
Pageof 11
Cancer Immunology Research|January 13, 2019
Association of Tumor Microenvironment T-cell Repertoire and Mutational Load with Clinical Outcome after Sequential Checkpoint Blockade in MelanomaErik Yusko, Marissa Vignali, Richard K Wilson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 13, 2009
A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanomaJeffrey Weber, John A Thompson, Omid Hamid, et al.
Cancer Immunity|July 9, 2013
Randomized phase I pharmacokinetic study of ipilimumab with or without one of two different chemotherapy regimens in patients with untreated advanced melanomaJeffrey Weber, Omid Hamid, Asim Amin, et al.
The Journal of Rheumatology|December 3, 2010
Botulinum toxin intramuscular injections for neck pain: a systematic review and metaanalysisPierre Langevin, Janet Lowcock, Jeffrey Weber, et al.
Cancer Imaging : the Official Publication of the International Cancer Imaging Society|January 23, 2015
Metabolic response by FDG-PET to imatinib correlates with exon 11 KIT mutation and predicts outcome in patients with mucosal melanomaKatherine Zukotynski, Jeffrey T Yap, Anita Giobbie-Hurder, et al.
Melanoma Research|August 18, 2020
Preliminary analysis of distinct clinical and biologic features of bone metastases in melanomaMelissa A Wilson, Judy Zhong, Paul Johannet, et al.
Melanoma Research|August 22, 2013
The antimelanoma activity of the histone deacetylase inhibitor panobinostat (LBH589) is mediated by direct tumor cytotoxicity and increased tumor immunogenicityDavid M Woods, Karrune Woan, Fengdong Cheng, et al.
The Oncologist|May 13, 2017
Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of EncephalitisJames Larkin, Bartosz Chmielowski, Christopher D Lao, et al.
The Journal of Dermatology|October 23, 2019
Adjuvant therapy with nivolumab versus ipilimumab after complete resection of stage III/IV melanoma: Japanese subgroup analysis from the phase 3 CheckMate 238 studyKenji Yokota, Hiroshi Uchi, Hisashi Uhara, et al.
Cancer|December 20, 2002
Granulocyte-macrophage-colony-stimulating factor added to a multipeptide vaccine for resected Stage II melanomaJeffrey Weber, Vernon K Sondak, Ronaldo Scotland, et al.
Pageof 11